Evaluation of the diagnostic accuracy of Computer-Aided Detection of tuberculosis on Chest radiography among private sector patients in Pakistan by Zaidi, S.M.A. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/196901
 
 
 
Please be advised that this information was generated on 2019-06-02 and may be subject to
change.
1Scientific REPoRTS |  (2018) 8:12339  | DOI:10.1038/s41598-018-30810-1
www.nature.com/scientificreports
Evaluation of the diagnostic 
accuracy of Computer-Aided 
Detection of tuberculosis on Chest 
radiography among private sector 
patients in Pakistan
Syed Mohammad Asad Zaidi1, Shifa Salman Habib1, Bram Van Ginneken2, 
Rashida Abbas Ferrand3, Jacob Creswell4, Saira Khowaja5 & Aamir Khan5
The introduction of digital CXR with automated computer-aided interpretation, has given impetus 
to the role of CXR in TB screening, particularly in low resource, high-burden settings. The aim of this 
study was to evaluate the diagnostic accuracy of CAD4TB as a screening tool, implemented in the 
private sector in Karachi, Pakistan. This study analyzed retrospective data from CAD4TB and Xpert 
MTB/RIF testing carried out at two private TB treatment and diagnostic centers in Karachi. Sensitivity, 
specificity, potential Xperts saved, were computed and the receiver operator characteristic curves 
were constructed for four different models of CAD4TB. A total of 6,845 individuals with presumptive 
TB were enrolled in the study, 15.2% of which had MTB + ve result on Xpert. A high sensitivity (range 
65.8–97.3%) and NPV (range 93.1–98.4%) were recorded for CAD4TB. The Area under the ROC curve 
(AUC) for CAD4TB was 0.79. CAD4TB with patient demographics (age and gender) gave an AUC of 
0.83. CAD4TB offered high diagnostic accuracy. In low resource settings, CAD4TB, as a triage tool 
could minimize use of Xpert. Using CAD4TB in combination with age and gender data enhanced the 
performance of the software. Variations in demographic information generate different individual risk 
probabilities for the same CAD4TB scores.
Tuberculosis (TB) remains a major cause of morbidity and mortality globally. In 2015, there were an estimated 
10.4 million incident cases of TB and 1.8 million TB deaths1. Active case finding programs are being increasingly 
utilized to reduce the case-detection gap2,3.
In recent years, there has been growing interest in the use of chest x-rays (CXR) as a screening tool for TB 
within active and enhanced case finding programs4. Recent TB prevalence surveys have shown that CXR has 
higher sensitivity than verbal screening for identifying pulmonary TB5–7. Previously, costs, limited access to x-ray 
facilities, maintenance of equipment, availability of trained personnel, poor specificity and inter-observer varia-
tion meant that the role of CXR within diagnostic algorithms was limited8.
The advent of digital chest radiography along with software capable of automated interpretation such as the 
“Computer Assisted Diagnosis for TB” (CAD4TB) software developed by the Diagnostic Image Analysis Group 
of the Radboud University Medical Centre has prompted reconsideration of the role of CXR in TB screening, par-
ticularly in low resource, high-burden settings9. Long-term use of digital radiography is cost-efficient compared 
to conventional radiography as it eliminates recurring costs related to reagent use and radiologists10. Currently, 
CAD4TB is the only scoring software that has been evaluated and is being implemented in programmatic set-
tings. Encouraging findings on the diagnostic accuracy of CAD4TB has been reported from sub-Saharan Africa, 
and most recently from Bangladesh11–15.
1Community Health Solutions, Karachi, 74000, Pakistan. 2Radboud University Medical Center, 6525 GA, Nijmegen, 
Netherlands. 3London School of Hygiene and Tropical Medicine, London, WC1E 7HT, United Kingdom. 4StopTB 
Partnership, 1214 Geneva, 1214, Vernier, Switzerland. 5Interactive Research & Development, Karachi, 75190, 
Pakistan. Correspondence and requests for materials should be addressed to S.S.H. (email: shifa.habib@
chshealthcare.org)
Received: 2 November 2017
Accepted: 31 July 2018
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2Scientific REPoRTS |  (2018) 8:12339  | DOI:10.1038/s41598-018-30810-1
The need for improved approaches for screening has acquired greater pertinence following the introduction of 
sensitive rapid molecular diagnostics for TB such as Xpert MTB/RIF (Xpert) testing16–18. However, the scale-up of 
Xpert testing is limited in resource-constrained countries by high costs of test cartridges19–22.
An increasing body of evidence from high burden countries suggests that the use of digital CXR equipment 
and the automated reading of CXR with Computer Aided Detection (CAD), as a pre-screening tool, in conjunc-
tion with an expensive molecular test such as Xpert can improve case finding efforts23.
The use of CAD4TB is still in development phase, and the World Health Organization (WHO) has not devel-
oped any formal guidelines or recommendations for its use due to limited evidence. The aim of this study was 
to evaluate the diagnostic accuracy of CAD4TB as a screening tool, in Karachi, Pakistan, a megacity with a high 
TB prevalence and a substantial burden of undiagnosed TB. Similar studies, reporting diagnostic accuracy using 
Xpert MTB/RIF as the reference standard have been reported from Zambia in 2013 and Bangladesh in 201713,14. 
Other studies from Zambia, Tanzania, South Africa and England have evaluated CAD4TB against the reference 
standard of culture15,24–26. Our current study is another data point in the series of studies, carried out in Pakistan. 
In addition, we also investigated whether different models of CAD4TB implementation that included routinely 
collected programmatic data such as age and gender can potentially enhance the diagnostic accuracy of the soft-
ware and yield of TB case-detection.
Methods
Study design and setting. Pakistan has the fifth highest burden of tuberculosis in the world and the third 
largest number of undiagnosed TB cases1. Of the estimated 510,000 new TB cases, only 331 809 (65%) were 
notified to the National Tuberculosis Program (NTP) in 2015, making increased case-detection and notification 
a key priority27. Currently, smear microscopy is predominantly used as a diagnostic test in a majority of facilities 
in Pakistan28.
The study was conducted at two purpose built TB treatment and diagnostic centers, called “Sehatmand 
Zindagi” (Healthy Life) centers, in Karachi, Pakistan, from October 2013 to September 2015. These centers are 
located in low-middle income neighborhoods of Karachi, Nazimabad and Korangi. In addition to digital CXR 
equipment with CAD4TB, Xpert testing was carried out at both centers, with initiation of treatment among those 
diagnosed with TB.
The study was embedded within a broader programme implementing enhanced case finding, whereby 
community-health workers screened all individuals attending private health providers’ clinics, in the vicinity of 
the centers, using the WHO TB symptom screen29, that is screening for the presence of either of the following: 
cough of any duration, fever, hemoptysis, night sweats, weight loss. Following a clinical evaluation by the health 
providers, those identified with presumptive TB were referred to the centers for further investigation. The target 
population for this study included individuals with presumptive TB referred by the private providers from the 
catchment area of the centres, as well as individuals with symptoms who self-referred for investigation for TB. All 
participants underwent a paid digital CXR (USD 3–5) and were requested to provide a sputum sample for free of 
cost Xpert testing.
Chest X-Ray scoring procedures. The CXRs were scored for abnormalities suggestive of pulmonary TB 
by a software system CAD4TB (version 3.07, Diagnostic Image Analysis Group, The Netherlands). CAD4TB was 
developed utilizing machine learning methods and was trained using labeled samples to differentiate between 
normal and abnormal x-ray images. The software has two abnormality detection systems that is textural abnor-
mality and shape abnormality systems, which analyze the abnormalities in the unobscured lung fields that have 
been segmented automatically. The software then uses outputs from its detection systems as image descriptive 
features to train a k-NN classifier to compute a cumulative abnormality score (Range 0–95) for each CXR13,30. A 
higher score is indicative of more serious abnormality suggestive of TB. A CAD4TB threshold score of 50 was 
used for this population determined using previously collected CXR data in a similar population. All individuals 
with high CAD4TB scores (50 or greater) were referred back to their consulting physicians for further clinical 
evaluation.
Data management and analysis. All individuals attending the TB centers were registered online using an 
open-source platform (Open MRS), by allocation of a unique patient ID, against which baseline information and 
history of presenting symptoms were recorded. Distribution of CAD4TB scores was compared for various patient 
characteristics such as age, gender, symptoms and Xpert result. Sensitivity, specificity, positive predictive value 
(PPV) and negative predictive value (NPV) were calculated for each of the TB symptoms using Xpert result as 
the standard. Univariate and multivariate associations of CAD4TB score, age, gender and symptoms (as explan-
atory variables) with TB infection (defined as a positive Xpert result) were computed. Logistic regressions were 
performed with MTB detection as the outcome variable and CAD4TB score, age and gender as the explanatory 
variables (Model 1 and 3). Adjusted analyses were subsequently performed through backward step-wise multi-
variate logistic regression using Akaike’s Information Criteria (AIC) to select the final, parsimonious model where 
symptoms where included as predictors of TB (Model 2 and 4). The AIC is an estimator that provides the relative 
quality of various statistical models and allowed for the selection of the most suitable set of predictor variables 
for the final model. Inclusion of the full set of symptoms screened was selected through the AIC for Models 2 and 
4. Receiver Operator Characteristic (ROC) curves were constructed for four prediction models for TB, namely: 
Model 1 (CAD4TB score only), Model 2: (CAD4TB score, symptoms), Model 3: (CAD4TB score, Age, Gender) 
and Model 4 (CAD4TB score, age, gender, symptoms). Area-Under the Curve (AUC) statistics were obtained for 
each ROC curve and confidence intervals were calculated to investigate statistical differences in discriminatory 
accuracy of the prediction models. Sensitivity, Specificity, PPV and NPV for CAD4TB cutoff thresholds at scores 
of 50, 80 and 90 were obtained for the four prediction models by determining their predicted probabilities for 
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TB detection. These cut offs were selected based on the CAD4TB score distribution of the study population, with 
score 50, 80 and 90 being at the 25th, 50th percentile 75th percentile approximately.
A range of predicted probabilities for each CAD4TB score were obtained from the two models that included 
CAD4TB with demographic information (age and gender) and symptoms. Locally weighted regressions were 
carried out for the range of predicted probabilities for both models against CAD4TB scores and were used to 
determine the corresponding predicted probability for MTB detection at the four CAD4TB cut-offs. Predicted 
probabilities of TB were computed at each CAD4TB cutoff threshold. These estimated the risk of TB detection at 
each CAD4TB score. These were used to estimate the number of TB cases missed, Xpert cartridges reduced (due 
to reduced number of individuals with a CAD4TB score above the threshold) and yield (number of MTB positive 
results out of all those tested) on Xpert test for the four models. All data analysis was carried out using STATA 
Statistical Software (Stata Corporation Version 11. College Station, TX, USA).
Ethical Approval and informed consent. Ethical approval for the study obtained from the Institutional 
Review Board (IRB) of Interactive Research & Development that is registered with the Department of Health and 
Human Services, USA. The methods were carried out in accordance with the relevant guidelines and regulations. 
Verbal informed consent was obtained from the participants before carrying out screening activities under the 
project. De-identified data was provided for analysis to the study researchers, whereas all patient screening and 
diagnostic information was secured on a password-protected server.
Results
A total of 6,845 individuals with presumptive TB were enrolled in the study between October 2013 to September 
2015. Out of these, 755 individuals, with invalid, error, no result were excluded from the analysis. The median 
age of participants was 38.9 (IQR 17.2) years and 3,018 (49.6%) were male. The majority of individuals included 
in the study reported symptoms of cough (87.5%) and fever (76.1%) (Table 1). Hemoptysis and nightsweats were 
reported in 13.2% and 30.5% of the study participants respectively. A total of 925 individuals enrolled in the study 
(15.2%) had MTB + ve results on Xpert (Fig. 1). The majority of (90.2%) people with a MTB + ve result on Xpert 
had a CAD4TB score >80. However, a high proportion of individuals (74.2%) that tested as MTB-ve also had 
scores >80 (Table 1).
CAD4TB scores
All N (%) <=20 n (%) 21–40 n (%) 41–60 n (%) 61–80 n (%) 81–95 n (%) p-value*
Gender <0.001
Male 3,018(49.6) 51(31.7) 222(40.9) 421(41.0) 549(48.7) 1,775(54.9)
Female 3,072(50.4) 110(68.3) 321(59.11) 605 (59.0) 578 (51.3) 1,458(45.1)
Age <0.001
<=20 852(14) 24(14.9) 90(16.6) 188(18.3) 177(15.7) 373(11.5)
21–40 2,591(42.6) 101(62.7) 295(54.3) 537(52.3) 489(43.4) 1,169(36.2)
41–60 1,732(28.4) 33(20.5) 133(24.5) 246(24) 343(30.4) 977(30.2)
>60 915 (15.0) 3(1.9) 25(4.6) 55(5.4) 118(10.4) 712(22.1)
Symptoms
Cough 0.59
No 761(12.5) 17(10.6) 69(12.7) 176(17.2) 162(14.4) 337(10.4)
<2 weeks 4,968(81.6) 136(84.5) 445 (82) 796 (77.6) 902(80.0) 2,689 (83.2)
>2 weeks 361(5.9) 8(5) 29(5.34) 54(5.3) 63(5.6) 207(6.4)
Fever <0.001
No 1,455(23.9) 43(26.7) 139(25.6) 283(27.6) 305(27.1) 685(21.2)
Yes 4,635(76.1) 118(73.3) 404(74.4) 743(72.4) 822(72.9) 2,548(78.8)
Hemoptysis <0.001
No 5,287(86.8) 134(83.2) 480(88.4) 912(88.9) 1,004(89.1) 2,757(85.3)
Yes 803(13.2) 27(16.8) 63(11.6) 114(11.1) 123(10.9) 476(14.7)
Night sweats <0.01
No 4,232(69.5) 112(69.6) 379(69.8) 730(71.2) 831 (73.7) 2,180 (67.4)
Yes 1,858(30.5) 49(30.4) 164(30.2) 296(28.9) 296 (26.3) 1,053 (32.6)
Xpert MTB/RIF 
result <0.001
MTB not detected 5,165(84.8) 159(98.8) 535(98.5) 1,003(97.8) 1,069 (94.9) 2,399(74.2)
MTB detected 925(15.2) 2(0.2) 8(1.5) 23(2.2) 58(5.1) 834(25.8)
Table 1. Baseline characteristics of individuals with presumptive TB by Computer-Aided Detection of TB 
(CAD4TB) scores, visiting TB diagnostic and treatment centers in Karachi, Pakistan (Q3- 2013 to Q2- 2015). 
(N = 6090). *Significance testing was done using the chi-squared test.
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Cough <2 weeks (OR 2.05, CI 1.51–2.81) was the strongest predictor of TB disease in the final adjusted mod-
els for MTB detection (Table 2). Increasing age (OR 0.96, 95% CI: 0.96–0.97) and female gender were inversely 
associated with a positive Xpert result (OR 0.79, 95% CI: 0.68–0.93).
A high sensitivity (range 65.8–95.3%) and NPV (range 93.1–98.4%) were recorded for CAD4TB (Table 3). 
For each model, increasing CAD4TB score thresholds, improved yield of TB case detection, with corresponding 
increase in specificity and decrease in sensitivity. Using the symptom screen alone, cough of <2 weeks and fever, 
had higher sensitivities (93.8% and 85.7% respectively) and lower specificities (14.5% and 25.6% respectively) 
compared to other symptoms (Fig. 2). All symptoms had high negative predictive values and low positive predic-
tive values (Fig. 2).
For each of the models, at higher CAD4TB scores the number of Xpert tests carried out was reduced, however, 
it led to more patients being classified as false-negatives (TB cases missed). At a CAD4TB score of 90, a total of 
3,539 Xpert tests will be saved using Model 1 (CAD4TB scores only), 4163 with Model 2 (CAD4TB scores and 
symptoms), 4,577 will be saved in Model 3 (CAD4TB scores, age and gender), and 4,465 in Model 4 (CAD4TB 
scores with age, gender and symptoms). The TB cases missed were lowest for a CAD4TB score of 50, 2.7%, 3.2%, 
3.7% and 4.2% respectively for the four models. The MTB yield at a score of 90 using the four models was 30.8%, 
35%, 40.2% and 39.3% respectively.
Figure 1. Screening algorithm. Screening and diagnostic algorithm employed for people with presumptive TB 
visiting TB diagnostic and treatment centers in Karachi, Pakistan (Q3- 2013 to Q2- 2015).
Explanatory Variable OR* 95% CI p-value* Adjusted OR* 95% CI p-value*
Age 0.98 0.97–0 0.98 <0.01 0.96 0.96–0.97 <0.01
Gender (reference group male) 0.90 0.78–1.03 0.13 0.79 0.68–0 0.93 0.004
CAD4TB Score (reference score 0) 1.08 1.08–1.09 <0.01 1.09 1.09–1.10 <0.01
Symptoms^
None (reference)
Cough
<2 weeks 2.58 1.94–3.45 <0.01 2.05 1.51–2.81 <0.01
>2 weeks 3.00 2.03–4.40 <0.01 2.04 1.34–3.12 0.001
Fever 2.07 1.7–2.51 <0.01 1.47 1.18–1.82 <0.01
Hemoptysis 1.57 1.30–1.89 <0.01 1.35 1.09–1.67 0.005
Night sweats 1.49 1.29–1.73 <0.01 1.22 1.04–1.44 0.017
Table 2. Predictors for TB detection among individuals tested using Xpert MTB/RIF, visiting TB diagnostic and 
treatment centers in Karachi, Pakistan (Q3- 2013 to Q2- 2015). N = 6090. *Significance testing has been done 
using chi-squared test. ^Symptoms were coded as binary variables.
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The Area under the ROC curve (AUC) for the model with only CAD4TB scores as predictor for MTB detec-
tion (Model 1) was 0.79 (95% CI: 0.78–0.81) (Fig. 3) and for Model 2 using CAD4TB scores and symptoms was 
0.81. Inclusion of patient demographics (age and gender) to CAD4TB scores (Model 3) increased the AUC to 
0.83 (95% CI: 0.82–0.85). A combined model of CAD4TB scores, symptoms, age and gender (Model 4) further 
increased the AUC to 0.84 (95% CI: 0.82–0.85), however this was not significantly different compared to Model 3.
Table 4 describes a sample of the predicted probabilities for various combination of age and gender for the 
same selected CAD4TB scores.
CAD Score Sensitivity Specificity PPV NPV
Xpert tests 
saved
Total Xpert 
tests
TB Cases 
Missed MTB+
MTB 
Yield
No Triage Test
— — — — — — 6,090 — 925 15.2%
Model 1: CAD4TB Only (AUC 0.79, 95% CI: 0.78–0.81)
50 97.3% 30.3% 20.0% 98.4% 1590 4500 25(2.7%) 900(97.3%) 20.0%
80 91.0% 50.7% 24.9% 96.9% 2702 3388 83(9.0%) 842(91.0%) 24.9%
90 85.0% 65.8% 30.8% 96.1% 3539 2551 139(15.0%) 786(85.0%) 30.8%
Model 2: CAD4TB, Symptoms (AUC 0.81, 95% CI: 0.79–0.82)
50 96.75% 30.37% 19.92% 98.12% 1601 4489 30 (3.2%) 894(96.8%) 19.9%
80 87.45% 61.40% 28.85% 96.47% 3289 2801 116(12.5%) 808(87.5%) 28.8%
90 73.05% 75.75% 35.03% 94.01% 4163 1927 249(26.9%) 675(73.1%) 35.0%
Model 3: CAD4TB, Age, Gender (AUC 0.83, 95% CI: 0.82–0.85)
50 96.3% 34.8% 20.9% 98.1% 1829 4261 34(3.7%) 891(96.3%) 20.9%
80 82.3% 66.9% 30.8% 95.5% 3620 2470 164(17.7%) 761(82.3%) 30.8%
90 65.8% 82.5% 40.2% 93.1% 4577 1513 316(34.2%) 609(65.8%) 40.2%
Model 4: CAD4TB, Age, Gender, Symptoms (AUC 0.84, 95% CI: 0.82–0.85)
50 95.8% 37.5% 21.5% 98.0% 1973 4117 39(4.2%) 886(95.8%) 21.5%
80 82.8% 68.5% 32.0% 95.7% 3695 2395 159(17.2%) 766(82.8%) 32.0%
90 69.1% 80.9% 39.3% 93.6% 4465 1625 286(30.9%) 639(69.1%) 39.3%
Table 3. Sensitivity, Specificity, Positive predictive Value, Negative Predictive Value at different CAD4TB score 
thresholds among individuals tested using Xpert MTB/RIF, visiting TB diagnostic and treatment centers in 
Karachi, Pakistan (Q3–2013 to Q2–2015).
Figure 2. Symptomatic screening. Sensitivity, Specificity, Positive Predictive Value and Negative Predictive 
Value of symptomatic screening for TB of patients tested using Xpert MTB/RIF, visiting TB diagnostic and 
treatment centers in Karachi, Pakistan (Q3–2013 to Q2–2015).
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Figure 3. Diagnostic accuracy of CAD4TB. ROC curves yielded by the models evaluated in this study. 
The Area under the ROC curve (AUC) for the model with only CAD4TB scores as predictor for MTB 
detection (Model 1) was 0.79 (95% CI: 0.78–0.81). Model 2 (CAD4TB scores and symptoms) and model 
3 (CAD4TB + symptoms + age + gender) yielded AUC of 0.81 (0.79–0.82) and 0.83 (95% CI: 0.82–0.85) 
respectively. Combined model using of symptoms, CAD4TB scores and age and gender (Model 4) yielded AUC 
of 0.84 (95% CI: 0.82–0.85).
CAD4TB score Gender Age
Predicted Probability 
for MTB Detection* Risk for TB**
50 F 51 0.004 Low
50 M 51 0.005 Low
50 M 32 0.008 Low
50 F 32 0.01 Low
50 M 21 0.012 Low
50 F 21 0.016 Low
80 M 56 0.051 Low
80 F 56 0.065 Low
80 M 36 0.102 Medium
80 F 36 0.127 Medium
80 M 22 0.16 Medium
80 F 22 0.198 Medium
90 M 61 0.101 Medium
90 F 61 0.127 Medium
90 M 41 0.192 Medium
90 F 41 0.234 High
90 M 30 0.263 High
90 F 30 0.316 High
90 M 19 0.35 High
90 F 19 0.411 High
Table 4. Sample of probabilities and risk for TB from a prediction model utilizing Computer Aided Detection 
for TB (CAD4TB) and demographic data from individuals visiting TB diagnostic and treatment centers, in 
Karachi (Q3 2013–Q2 2015). *Predicted probabilities from multiple logistic regression model using CAD4TB 
and demographic information that is age and gender(Model 2). **Arbitrary cut-offs for TB risk (Female gender, 
lower age, and high CAD4TB scores associated with greater risk for TB).
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Discussion
Our study evaluated the performance of CAD4TB software as a screening tool for the detection of tuberculosis 
in a low-resource, high burden, non-HIV setting, using Xpert as the reference test. This study is one of the largest 
such evaluations of CAD4TB from a programmatic setting. In our study, CAD4TB was able to correctly identify a 
high proportion of people who were diagnosed with TB on Xpert and hence could potentially reduce the number 
of expensive molecular tests needed to detect TB in our sample of patients.
While the use of Xpert in programmatic settings has expanded in recent years, the WHO has also recom-
mended use of more cost effective diagnostic algorithms through screening tools such as CXR25,29,31. Development 
of software that offer automated interpretation of CXRs, represents an important milestone that can link tech-
nological innovations to mass-screening programs for tuberculosis. The utilization of CAD4TB as a triage tool, 
to pre-screen individuals for Xpert cannot only, improve case-detection in screening programs but also possibly 
reduce program costs32.
The findings from this study indicate that CAD4TB offers high diagnostic accuracy. CAD4TB scoring can 
be utilized to triage individuals for Xpert testing as individuals with a low CAD4TB score had a low probability 
of being tested positive for TB. In resource constrained settings such as Pakistan, with limited funds to support 
Xpert testing for all people with presumptive TB, using a triage tool like CAD4TB could promote more rational 
use of Xpert by minimizing the number of cartridges used. This is also relevant for facilities where an onsite radi-
ologist may not always be available to evaluate the CXR.f It is important to note that the savings offered through 
reduced Xpert tests need to be offset with the cost of acquiring and maintaining digital X-ray systems. However, 
a detailed discussion on the costing and policy implications for mass-screening using CXR is beyond the scope 
of this study. High sensitivity (range 85–97.3%) and NPV (range 96.1–98.4%) were recorded for CAD4TB at 
the score cut-offs utilized in the analysis, which is similar to what has been reported for CXR in other study 
settings18,33,34. The relatively lower specificity (range 30.3–65.7%) and PPV (20–30.8%) were also consistent with 
findings from another study evaluating CAD4TB13.
A high AUC (0.79) was recorded from the model using CAD4TB alone as a screening tool (Model 1). Other 
studies from Zambia and Bangladesh that also used Xpert as the reference test reported AUCs of 0.71 and 0.74 
respectively13,14. Studies from Africa, using culture as the reference test reported AUC in the range 0.71–0.8435. 
Our results therefore support investigations elsewhere suggesting that CAD4TB performs well in detecting 
radiological abnormalities11–14. To date, the highest AUC has been reported with the version 3.07 of CAD4TB 
(compared to older versions)35. With newer versions available and being increasingly utilized by programmes, 
it is expected that a superior performance of CAD4TB software will be found in future evaluations using newer 
versions, with improved machine learning capacity. While the combined use of CAD4TB and symptoms has been 
evaluated in a previous study12, this is one of the first studies that have evaluated CAD4TB in combination with 
symptoms as well as demographic information (age and gender). Using CAD4TB in combination with demo-
graphic data enhanced the performance of the software, generating a higher AUC (0.83), while such information 
such as age and gender are routinely captured in screening programmes. However, including clinical symptoms 
to the model with demographics and CAD4TB did not significantly increase accuracy as was hypothesized by a 
previous study13. Another study from South Africa, reported a superior performance of a combination framework 
using both CAD4TB scores and symptoms (AUC 0.84)12. Symptoms may not have contributed to improved per-
formance in our setting as the study population included individuals that were referred for investigations (includ-
ing self-referrals). This may have led to pre-screening of individuals thereby limiting the added discrimination 
offered by symptoms. Addition of symptoms improved specificity but decreased sensitivity as a lower number of 
individuals would have been screened positive under Model 4, and a larger number of TB cases were missed. In 
order to obtain a precise estimate of the AUC and to detect differences in the AUC between the models, a large 
sample size was included in the study. Since the data was obtained from a programmatic setting rather than a 
controlled investigation, a higher proportion of MTB-ve individuals were enrolled reflecting the prevalence of 
the disease in this population.
The increased diagnostic accuracy offered through demographic data can be utilized to further enhance the 
yield for Xpert testing than through CAD4TB alone. In this study, we used the dataset to generate a range of pre-
dicted probabilities for TB detection using a combination of CAD4TB scores, age and gender, like those shown 
in Table 4, that can be used to devise risk categories for patients identified through screening, further refining the 
triage process. Our study demonstrates that for the same CAD4TB scores, variations in demographic information 
such as age and gender can generate different individual risk probabilities. For example, at a CAD4TB score of 80, 
a male aged 56 years may have a low probability (5.1%) of being identified as MTB + ve on Xpert compared to a 
female aged 22 years who may have a higher probability (19.8%) (Table 4). Individualized risk scores could, there-
fore, assist frontline healthcare workers make informed decisions about whom to test. Sputum samples for Xpert 
testing may be collected for those with high risk for TB, and repeat tests or clinical evaluations may be carried out 
for those with medium to high risk, that can potentially save Xpert cartridges, improve testing yields and make 
programs more cost-effective. In addition to demographic data, routinely collected programmatic information 
such as history of TB contact, diabetes status and smoking history can be further utilized by future programs to 
create personalized risk scores. It must be noted that symptoms, while not offering improved accuracy in this 
study, may be useful in community-settings in active case finding programs where a large number of asympto-
matic individuals are also among those screened and may further help improve yield on Xpert.
Our study findings also demonstrate that for increasing CAD4TB score thresholds, the sensitivity decreased, 
with corresponding increase in specificity, resulting in more TB cases but providing a higher yield (Table 3). 
Similar findings have been reported from a study in South Africa where 11% of TB cases would have been missed 
using a threshold score that would have triaged 40% of suspects for Xpert testing25. However, individualized risk 
assessment, may diminish the need to set CAD4TB thresholds for programs broadly with greater reliance on 
testing based on personalized assessment.
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An additional benefit of utilizing digital X-rays is increased capacity for clinical diagnosis of TB. Images can 
be archived online using cloud-based software allowing radiologists or clinical officers at TB facilities high qual-
ity images for diagnostic evaluation. In addition, mass-screening programs with X-rays are more likely to gen-
erate community interest and support mobilization than conventional screening camps with health workers. 
However, additional operational considerations continue to be relevant regardless of the modality of screening 
used. Improvements in processes such as health communication activities to promote screening among asympto-
matic individuals, adequate resources for sputum induction, increased diagnostic capacity for testing, additional 
clinical staff for examining bacteriologically negative cases and engineers for providing equipment and software 
maintenance, will all be required to make screening and community referrals more effective. Since CAD4TB does 
not differentiate CXR abnormalities that may be observed in other conditions, such as pneumonia, lung cancer, 
etc., a significant number of people without TB are likely to be referred for diagnostic testing14. Algorithms and 
pathways to care will need to be developed for managing the diagnostic workup and treatment for these individ-
uals. This is especially pertinent for developing countries with donor supported TB programs as diagnostics and 
treatment for other pulmonary pathologies are not funded.
Our study has certain limitations. The major limitation was that Xpert, and not mycobacterial culture was used 
as the reference standard, whereby Xpert negative, culture positive TB cases may have been missed. Individuals 
that were unable to expectorate sputum and cases with invalid or error results on xpert (for which additional 
sputum samples could not be obtained to re-run the test), were excluded from the study. These factors may have 
decreased the number of patients classified as MTB + ve and affected the accuracy of the results. An evaluation 
of the performance of CAD4TB compared with human readers was beyond the scope of this analysis as this 
has been conducted extensively in a number of studies. These evaluations utilized a combination of readings by 
clinical officers and radiologists and the performance of CAD4TB was found to have been comparable to those 
of human readers and also has the potential to reduce inter-reader and intra-reader variability and detection 
errors11,34–36. While these early studies have demonstrated the effectiveness of CAD4TB in place of medical staff, 
further studies such as ours that utilize a biological reference can further support the use of CAD4TB in screen-
ing programs. Finally, the external validity of our study may be limited for active-case finding programs as the 
participant enrollment was carried out at a facility-based setting, and the results may not be generalizable to the 
community setting where a large number of asymptomatic people with TB may also be present. We therefore 
recommend further studies to evaluate CAD4TB in the community setting such as through mobile X-ray units.
Conclusion
This study described the first use of CXRs supported with computer-aided detection as part of enhanced 
case-finding intervention in the private sector in Pakistan. It demonstrated CAD4TB has the potential to be 
used as a triage tool to carry out screening of symptomatic individuals who could be excluded from further 
testing to make screening programs more cost effective by saving the number of Xpert tests. With the large scale 
roll-outs of Xpert and CAD4TB in local programmatic settings, its use within different case finding approaches 
should be evaluated and compared. A follow-up study comparing different versions of CAD4TB is also recom-
mended. Screening algorithms need to be tailored to local contexts taking into account priorities for increased 
case-detection and resources required for testing additional individuals with presumptive TB.
Data availability. The datasets generated during and/or analysed during the current study are available from 
the corresponding author on reasonable request
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